153 related articles for article (PubMed ID: 12073790)
1. [Postprandial hyperglycemia. II. Pharmacological approaches].
Scheen AJ; Letiexhe MR; Geronooz I; Paquot N; Jandrain B
Rev Med Liege; 2002 Apr; 57(4):196-201. PubMed ID: 12073790
[TBL] [Abstract][Full Text] [Related]
2. Drug therapy of postprandial hyperglycaemia.
Mooradian AD; Thurman JE
Drugs; 1999 Jan; 57(1):19-29. PubMed ID: 9951949
[TBL] [Abstract][Full Text] [Related]
3. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
4. Postprandial hyperglycemia in patients with type 2 diabetes mellitus.
Sudhir R; Mohan V
Treat Endocrinol; 2002; 1(2):105-16. PubMed ID: 15765626
[TBL] [Abstract][Full Text] [Related]
5. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
6. [Postprandial hyperglycemia. I. Physiopathology, clinical consequences and dietary management].
Scheen AJ; Paquot N; Jandrain B; Lefèbvre PJ
Rev Med Liege; 2002 Mar; 57(3):138-41. PubMed ID: 12014260
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
8. alpha-Glucosidase inhibitors.
Lebovitz HE
Endocrinol Metab Clin North Am; 1997 Sep; 26(3):539-51. PubMed ID: 9314014
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological treatment of postprandial hyperglycemia].
Blickle JF
Diabetes Metab; 2000 Jun; 26 Suppl 2():20-4. PubMed ID: 10975046
[TBL] [Abstract][Full Text] [Related]
10. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
Dimitriadis GD; Tessari P; Go VL; Gerich JE
Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
[TBL] [Abstract][Full Text] [Related]
11. Successful use of acarbose to manage post-prandial glycaemia in two patients with type 1 diabetes on continuous subcutaneous insulin infusion.
Dash S; Crisp S; Hartnell S; Donald S; Davenport K; Simmons D; Evans M
Diabetes Res Clin Pract; 2012 Mar; 95(3):e49-51. PubMed ID: 22136721
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
[TBL] [Abstract][Full Text] [Related]
13. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
Baron AD; Kim D; Weyer C
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
[TBL] [Abstract][Full Text] [Related]
14. Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes.
Göke B; Herrmann C; Göke R; Fehmann HC; Berghöfer P; Richter G; Arnold R
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():25-30. PubMed ID: 8001623
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
17. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
18. α-Glucosidase inhibitory effect of resveratrol and piceatannol.
Zhang AJ; Rimando AM; Mizuno CS; Mathews ST
J Nutr Biochem; 2017 Sep; 47():86-93. PubMed ID: 28570943
[TBL] [Abstract][Full Text] [Related]
19. Recent developments and emerging therapies for type 2 diabetes mellitus.
Evans AJ; Krentz AJ
Drugs R D; 1999 Aug; 2(2):75-94. PubMed ID: 10820647
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
